Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baseline characteristics of actual enrolled patients. This collaboration will enhance the development of Axoltis’s NX210c by accelerating the … Read More